{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"55","value":"46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The amount of time between attainment of at least a minor response and disease progression.","dispersionType":"Full Range","groups":[{"description":"This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated Waldenstrom's macroglobulinemia (WM) patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.","id":"OG000","title":"Ibrutinib"}],"paramType":"MEDIAN","populationDescription":"All participants except one determined to be ineligible","reportingStatus":"POSTED","timeFrame":"6 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}